Supplementary Tables S1-S6 from Repurposing NAMPT Inhibitors for Germinal Center B Cell–Like Diffuse Large B-Cell Lymphoma

Raw data related to 1) Drug Sensitivity Screening; 2) Metabolic Profiling; 3) Transcript levels of NAD; 4) DepMap Depletion Score for NAD; 5) NP ratio in mutated vs WT GCB-DLBCL samples; 6) NP mRNA ratio in DLBCL primary cases